Abstract Cytidine RNA modifications have emerged as key regulators of tumor cancer biology, linking transcriptional control to metabolic adaptation and immune evasion. Among them, 5-methylcytidine (m⁵C) and N⁴-acetylcytidine (ac⁴C) represent dynamic and functionally complementary epitranscriptomic marks that operate through distinct regulatory layers. m⁵C, catalyzed by the NSUN family methyltransferases, primarily stabilizes pro-tumorigenic transcripts, enhances glycolysis, and suppresses antitumor immunity through modulation of cytokine and checkpoint pathways. In parallel, ac⁴C, mediated by the acetyltransferase NAT10, fine-tunes translational efficiency and proteostasis, enabling tumor cells to adapt to metabolic and therapeutic stress. Together, these modifications cooperatively remodel the tumor immune microenvironment by driving macrophage polarization, T-cell exhaustion, and attenuation of interferon signaling, establishing a durable immunosuppressive niche. Notably, pharmacologic or genetic inhibition of m⁵C- and ac⁴C-modifying enzymes reverses malignant phenotypes and restores sensitivity to immune checkpoint and metabolic therapies. Elucidating this two-layer cytidine epitranscriptomic architecture unveils new epigenetic dimensions of tumor plasticity and offers promising avenues for precision RNA-targeted oncology.
Zhong et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: